(IN BRIEF) AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US…
(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health,…
(IN BRIEF) AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration…